Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Virax Biolabs Group Limited (VRAX) had Return on Tangible Equity of -68.61% for the most recently reported fiscal year, ending 2026-03-31.
| Income Statement Financials | |
$0.01M |
|
$-5.02M |
|
$0.00M |
|
$0.01M |
|
$6.41M |
|
$-6.40M |
|
$0.47M |
|
$-5.93M |
|
$-5.93M |
|
$-5.03M |
|
$-5.03M |
|
$-5.03M |
|
$-5.03M |
|
$-6.40M |
|
$-5.96M |
|
0.40M |
|
0.40M |
|
$-12.64 |
|
$-12.64 |
|
| Balance Sheet Financials | |
$6.83M |
|
$1.17M |
|
$1.50M |
|
$8.32M |
|
$0.69M |
|
-- |
|
$0.30M |
|
$0.99M |
|
$7.33M |
|
$7.33M |
|
$7.33M |
|
0.58M |
|
| Cash Flow Statement Financials | |
$-4.62M |
|
$-0.26M |
|
$7.09M |
|
$4.23M |
|
$6.44M |
|
$2.21M |
|
$0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.97 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
61.90% |
|
-51515.17% |
|
-51515.17% |
|
-47981.26% |
|
-47753.55% |
|
-40439.10% |
|
$-4.88M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.46 |
|
796.58 |
|
-68.61% |
|
|
Return on Tangible Equity |
-68.61% |
-60.45% |
|
-68.61% |
|
$12.66 |
|
$-12.27 |
|
$-11.62 |
|